Hikma Pharmaceuticals PLC
Research Hikma Pharmaceuticals PLC (HIK) on Bullrun: market cap GBX 328.25B, P/E 12.1, dividend yield 2.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHIK
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyGBX
- Market capGBX 328.25B
- P/E12.1
- Dividend yield2.2%
- Financial periodFY2025
- RevenueUSD 3.35B
- Revenue growth7.1%
- Net incomeUSD 402.00M
- Free cash flowUSD 119.00M
- Gross margin43.0%
Valuation Snapshot
latest market cap is GBX 328.25B; P/E is 12.1; dividend yield is 2.2%.
Peer valuation comparison
Latest P/E is 12.11x versus a Healthcare sector median of 24.6x (50.8% below).
Latest dividend yield is 2.23% versus a Healthcare sector median of 1.84% (21.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.35B | USD 402.00M | USD 119.00M | 43.0% | 1.81 | USD 217.00M | USD 1.60B | USD 2.59B |
| FY2024 | USD 3.13B | USD 359.00M | USD 329.00M | 45.3% | 1.61 | USD 188.00M | USD 1.31B | USD 2.31B |
| FY2023 | USD 2.88B | USD 190.00M | USD 404.00M | 48.3% | 0.85 | USD 205.00M | USD 1.19B | USD 2.20B |
| FY2022 | USD 2.52B | USD 188.00M | USD 360.00M | 49.2% | 0.84 | USD 270.00M | USD 1.28B | USD 2.14B |
| FY2021 | USD 2.55B | USD 421.00M | n/a | 51.0% | 1.81 | USD 426.00M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-14 | GBX 328.25B | 12.1 | 4.0% | 0.64 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.64 GBX, yield 2.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 64.18 USD |
| FY2024 | 61.41 USD |
| FY2023 | 49.41 USD |
| FY2022 | 42 USD |
| FY2021 | 37.7 USD |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets.
ETFs that hold Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Inyova Impact Investing Fund | 3.54% | 0.95% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hikma Pharmaceuticals PLC's market cap?
Hikma Pharmaceuticals PLC's market capitalization is GBX 328.25B.
What is Hikma Pharmaceuticals PLC's P/E ratio?
Hikma Pharmaceuticals PLC's price-to-earnings (P/E) ratio is 12.1.
Does Hikma Pharmaceuticals PLC pay a dividend?
Hikma Pharmaceuticals PLC has a dividend yield of 2.2%.
What does Hikma Pharmaceuticals PLC do?
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market.